Chronic Lymphocytic Leukemia | Specialty

Fixed-Duration Venetoclax Triplet Active in CLL

January 1st 2019

Kerry A. Rogers, MD, discusses phase II findings of a trial with obinutuzumab, ibrutinib, and venetoclax and the future of dose-limited regimens in chronic lymphocytic leukemia.

Dr. Seymour on Updated Findings From the MURANO Trial in CLL

December 12th 2018

John F. Seymour, MBBS, PhD, clinical hematologist, associate director of Clinical Research, Peter MacCallum Centre, director of the integrated Haematology Department of the Peter MacCallum Cancer Centre and the Royal Melbourne Hospital, discusses the updated findings from the MURANO trial presented at the 2018 ASH Annual Meeting.

Acalabrutinib Achieves High Response Rates in CLL

December 11th 2018

Patients with newly diagnosed or relapsed/refractory chronic lymphocytic leukemia achieved objective response rates as high as 100% with either of 2 doses of the BTK inhibitor acalabrutinib, results of an open-label phase II trial showed.

Dr. Gauthier on Potential for CAR T Cells in CLL

December 11th 2018

Jordan Gauthier, MD, MSc, senior clinical research fellow, Fred Hutchinson Cancer Research Center, discusses the potential for chimeric antigen receptor T-cell therapy in the treatment of chronic lymphocytic leukemia.

Venetoclax/Rituximab Combo Achieves Durable, High MRD-Negative Status in CLL

December 5th 2018

The combination of venetoclax and rituximab for relapsed/refractor chronic lymphoblastic leukemia produced high rates of undetectable minimal residual disease, which was associated with prolonged progression-free survival, a new analysis of a randomized trial showed.

Dr. Seymour on Role of Ibrutinib in CLL

December 4th 2018

Erlene Seymour, MD, assistant professor of medicine, Karmanos Cancer Institute, Wayne State University, discusses the role of ibrutinib in the treatment of patients with chronic lymphocytic leukemia.

Mutation in BCL2 Protein Confers Resistance to Venetoclax

December 4th 2018

A newly discovered recurrent mutation in the B-cell leukemia/lymphoma 2 protein mediates clinical resistance to venetoclax in patients with chronic lymphocytic leukemia.

High MRD-Negative Rates Seen with Venetoclax in Patients With Relapsed/Refractory CLL

December 4th 2018

Patients with relapsed/refractory chronic lymphoblastic leukemia treated with single-agent venetoclax attained high rates of minimal residual disease in peripheral blood and bone marrow.

Ibrutinib/Rituximab Improves OS, PFS Versus FCR for Untreated CLL

December 4th 2018

The combination of ibrutinib and rituximab significantly improved overall survival and progression-free survival compared with standard fludarabine, cyclophosphamide, and rituximab for younger patients with chronic lymphocytic leukemia.

Phase III Data Showcase PFS Benefit With Frontline Ibrutinib/Obinutuzumab Combo in High-Risk CLL

December 4th 2018

The first-line combination of ibrutinib (Imbruvica) and obinutuzumab (Gazyva) was associated with a 77% reduction in the risk for disease progression or death compared with chemoimmunotherapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Dr. Gauthier on Findings for CD19-Targeted CAR T Cells Plus Ibrutinib in CLL

December 3rd 2018

Jordan Gauthier, MD, MSc, senior clinical research fellow, Fred Hutchinson Cancer Research Center, discusses a study comparing efficacy and toxicity of CD19-specific chimeric antigen receptor (CAR) T cells alone or in combination with ibrutinib in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL) during the 2018 ASH Annual Meeting.

Liso-Cel Demonstrates Durable Responses in Heavily Pretreated, High-Risk CLL

December 3rd 2018

Lisocabtagene maraleucel appeared tolerable and induced an 81.3% best overall response rate and 43.8% complete response rate in heavily pretreated, high-risk patients with chronic lymphocytic leukemia who previously received ibrutinib.

Ibrutinib/Venetoclax Combination Achieves High Rate of MRD Negativity in Relapsed/Refractory CLL

December 3rd 2018

The combination of ibrutinib and venetoclax is well tolerated and eradicates minimal residual disease in the marrow after 12 months in 39% of patients with relapsed/refractory chronic lymphocytic leukemia.

Ibrutinib/CAR T Cell Combo Active in CLL

December 2nd 2018

Concurrent treatment with ibrutinib and the CD19-targeted chimeric antigen receptor T-cell therapy JCAR014 was well tolerated and led to an overall response rate of 83% in patients with relapsed or refractory chronic lymphocytic leukemia.

Ibrutinib Established as Standard for Older CLL Patients

December 2nd 2018

Ibrutinib as monotherapy and combined with rituximab significantly improved progression-free survival compared with bendamustine plus rituximab as frontline therapy for older patients with chronic lymphocytic leukemia.

ASH 2018: Dr. O'Connor Shares Insight on MCL and T-Cell Lymphoma Advances

December 1st 2018

ASH 2018: Dr. Wierda Discusses Pivotal Updates in CLL

December 1st 2018

ASH 2018: Dr. Landgren Highlights Pivotal Myeloma Data

December 1st 2018

Dr. Mesa Discusses Exciting Abstracts on Myeloproliferative Neoplasms

December 1st 2018

Dr. Pagel Highlights the Top Abstracts From the 2018 ASH Annual Meeting

December 1st 2018